88 related articles for article (PubMed ID: 22780906)
41. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy.
Zhao J; Wang H; Hsiao CH; Chow DS; Koay EJ; Kang Y; Wen X; Huang Q; Ma Y; Bankson JA; Ullrich SE; Overwijk W; Maitra A; Piwnica-Worms D; Fleming JB; Li C
Biomaterials; 2018 Mar; 159():215-228. PubMed ID: 29331808
[TBL] [Abstract][Full Text] [Related]
42. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer.
Zhang B; Wang H; Jiang T; Jin K; Luo Z; Shi W; Mei H; Wang H; Hu Y; Pang Z; Jiang X
J Drug Target; 2018 Dec; 26(10):913-919. PubMed ID: 29533111
[TBL] [Abstract][Full Text] [Related]
43. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.
Cabral H; Murakami M; Hojo H; Terada Y; Kano MR; Chung UI; Nishiyama N; Kataoka K
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11397-402. PubMed ID: 23801758
[TBL] [Abstract][Full Text] [Related]
44. Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes.
Italiya KS; Basak M; Mazumdar S; Sahel DK; Shrivastava R; Chitkara D; Mittal A
Mol Pharm; 2019 Dec; 16(12):4954-4967. PubMed ID: 31647676
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Potential of Steroidal Alkaloids in Cancer and Other Diseases.
Jiang QW; Chen MW; Cheng KJ; Yu PZ; Wei X; Shi Z
Med Res Rev; 2016 Jan; 36(1):119-43. PubMed ID: 25820039
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of cyclopamine via conjugation with nonmetabolic sugars.
Goff RD; Thorson JS
Org Lett; 2012 May; 14(10):2454-7. PubMed ID: 22540932
[TBL] [Abstract][Full Text] [Related]
47. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
48. Copolymeric micelles for delivery of EGCG and cyclopamine to pancreatic cancer cells.
Sun L; Zhang C; Li P
Nutr Cancer; 2014; 66(5):896-903. PubMed ID: 24798568
[TBL] [Abstract][Full Text] [Related]
49. LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.
Wen D; Chitkara D; Wu H; Danquah M; Patil R; Miller DD; Mahato RI
Pharm Res; 2014 Oct; 31(10):2784-95. PubMed ID: 24789451
[TBL] [Abstract][Full Text] [Related]
50. Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.
Desale SS; Cohen SM; Zhao Y; Kabanov AV; Bronich TK
J Control Release; 2013 Nov; 171(3):339-48. PubMed ID: 23665258
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.
Pramanik N; Gupta A; Ghanwatkar Y; Mahato RI
J Control Release; 2024 Feb; 366():231-260. PubMed ID: 38171473
[TBL] [Abstract][Full Text] [Related]
52. Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis.
Cheng H; Liu Y; Chen G
BMC Urol; 2023 Aug; 23(1):135. PubMed ID: 37563710
[TBL] [Abstract][Full Text] [Related]
53. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.
Bhattarai RS; Kumar V; Romanova S; Bariwal J; Chen H; Deng S; Bhatt VR; Bronich T; Li W; Mahato RI
J Control Release; 2021 Jan; 329():585-597. PubMed ID: 33010334
[TBL] [Abstract][Full Text] [Related]
54. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy.
Zhou X; Shi K; Hao Y; Yang C; Zha R; Yi C; Qian Z
Asian J Pharm Sci; 2020 Jan; 15(1):26-41. PubMed ID: 32175016
[TBL] [Abstract][Full Text] [Related]
55. Redox-responsive hyaluronic acid-functionalized graphene oxide nanosheets for targeted delivery of water-insoluble cancer drugs.
Liu J; Zhang D; Lian S; Zheng J; Li B; Li T; Jia L
Int J Nanomedicine; 2018; 13():7457-7472. PubMed ID: 30532533
[TBL] [Abstract][Full Text] [Related]
56. Design of Hedgehog pathway inhibitors for cancer treatment.
Bariwal J; Kumar V; Dong Y; Mahato RI
Med Res Rev; 2019 May; 39(3):1137-1204. PubMed ID: 30484872
[TBL] [Abstract][Full Text] [Related]
57. A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma.
Parascandolo A; Laukkanen MO; De Rosa N; Ugolini C; Cantisani MC; Cirafici AM; Basolo F; Santoro M; Castellone MD
Oncotarget; 2018 Jan; 9(4):4496-4510. PubMed ID: 29435119
[TBL] [Abstract][Full Text] [Related]
58. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
Adiseshaiah PP; Crist RM; Hook SS; McNeil SE
Nat Rev Clin Oncol; 2016 Dec; 13(12):750-765. PubMed ID: 27531700
[TBL] [Abstract][Full Text] [Related]
59. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
60. The Role of Hedgehog Signaling in Tumor Induced Bone Disease.
Cannonier SA; Sterling JA
Cancers (Basel); 2015 Aug; 7(3):1658-83. PubMed ID: 26343726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
